Experience of Treating COVID-19 With Remdesivir and Convalescent Plasma in a Resource-Limited Setting: A Prospective, Observational Study.

Janak KoiralaPradip GyanwaliRobert B GerzoffSaroj BhattaraiBipin NepalRekha ManandharRuna JhaSanjib SharmaYuba Raj SharmaAnup BastolaHolly MurphySubhash AcharyaPrabhat AdhikariManita RajkarnikariKarishma M VaidyaChhabi L PanthiBihungum BistaGrishma GiriShambhu AryalSuman PantAkritee PokharelShristi KarkiSangita BasnetBhagawan KoiralaMeghnath Dhimalnull null

Published in: Open forum infectious diseases (2021)

This study demonstrates a safe rollout of CPT and REM in a resource-limited setting. Remdesivir recipients had less severe infection and better outcomes.ClinicalTrials.gov identifier. NCT04570982.

Keyphrases

coronavirus disease
sars cov
early onset
skeletal muscle
kidney transplantation